Introduction: Recent Developments
On June 30th, 2020, Galectin Therapeutics (GALT) announced the long-awaited commencement of their phase 3 NASH cirrhosis trial, NASH-RX. Recent events highlight the innovative and meaningful design of the NASH-RX trial, data from the NASH-CX trial, and competition fallouts.
Genfit (GNFT) announced the results of its phase 3 RESOLVE-IT trial, which was very interesting because the drug performed about as well as obeticholic acid in fibrosis reversal and NASH resolution combined, except that the placebo response was about twice as high, rendering the difference statistically insignificant [1